Saturday 17 October 2026 Export NTRB’s income statement to Excel — free account

Nutriband Inc.

Nutriband Inc.’s revenue for fiscal 2026 (year ended January 2026) was $2.0 million, down 4.80% from fiscal 2025. In the quarter to July 2026, revenue fell 29.7%, EPS grew 96.7%, free cash flow grew 55.5% and total debt fell 46.9%, each against the same quarter a year earlier.

6.22 0.05 −0.80%

Follow NTRB

Alert me

Market cap: $76.2M
P/E: 0.0×
Fwd P/E: 4.6×
Dividend yield: —
F-score: 3/9
Altman Z: 27.17
Beneish M: −3.51
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 56.81%

Capital & Financial Ratios $m

Market Cap 76.21

Revenue 1.62

Net Income (6.96)

Free Cash Flow (3.63)

Net Debt (3.40)

Current Ratio 4.21

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 4.55

P/S ratio 46.74

P/B ratio 14.20

Past 5Y EPS Growth —

This Y EPS Growth (526.26%)

Next Y EPS Growth 125.32%

Next Y revenue growth 34.04%

Next 5Y EPS Growth 9.36%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 70.45%

10-year low 10-year high

P/B against its own 10 years 62.44%

10-year low 10-year high

EV/Sales against its own 10 years 69.63%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	0	4	5	3
Receivables	0	0	0	0
Inventory	0	0	0	0
Other	—	—	—	—
	1	5	5	4

	2024	2025	2026	Q'26
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1	1	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	16.63%	(0.69%)
Cash Flow	—	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(1.25%)	(7.98%)

Revenue $m

	Apr	Jul	Oct	Jan	Year
’26	0	0	—	—	—
’26	1	1	0	0	2
’25	0	0	1	1	2
’24	0	1	0	1	2
’23	0	0	1	1	2
’22	0	0	0	0	1
’21	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Apr	Jul	Oct	Jan	Year
’26	(1)	(1)	—	—	—
’26	(1)	(1)	(2)	(1)	(5)
’25	(1)	(2)	(1)	(1)	(5)
’24	(1)	(1)	(1)	(1)	(4)
’23	(1)	(1)	(1)	(1)	(3)
’22	0	0	(1)	(1)	(3)
’21	0	0	0	0	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Apr	Jul	Oct	Jan	Year
’26	(1)	(1)	—	—	—
’26	(1)	(1)	(2)	(1)	(5)
’25	(1)	(2)	(1)	(1)	(5)
’24	(1)	(1)	(1)	(1)	(4)
’23	(1)	(1)	(1)	(1)	(3)
’22	0	0	(1)	(1)	(3)
’21	0	0	0	0	0

Fiscal quarters ending in the months shown.

EPS $

	Apr	Jul	Oct	Jan	Year
’26	(0.10)	(0.07)	—	—	—
’26	(0.12)	(2.12)	(0.32)	(0.08)	(2.58)
’25	(0.21)	(0.15)	(0.12)	(0.51)	(0.99)
’24	(0.13)	(0.11)	(0.22)	(0.23)	(0.69)
’23	(0.08)	(0.12)	(0.14)	(0.21)	(0.53)
’22	(0.04)	(0.07)	(0.23)	(0.46)	(0.81)
’21	(0.07)	(0.03)	(0.01)	(0.33)	(0.44)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	5.31	5.66	8.57	5.16	0.86	2.41	1.53	2.22	3.90	2.80	Analyst estimates 2027–2029 Powerpack
	High	7.03	43.54	40.80	16.92	27.43	8.96	5.15	9.60	11.78	9.19
People
People	Employees	2	10	7	3	5	13	3	3	3	3
	Revenue/emp, $m	0.00	0.00	0.04	0.12	0.19	0.11	0.69	0.70	0.71	0.68
Income, $m
Income, $m	Revenue	—	—	0	0	1	1	2	2	2	2
	Gross margin, %	—	—	(17.53)	(48.17)	33.52	35.46	36.08	41.34	34.74	27.80
	EBT	0	(3)	(3)	(3)	(3)	(6)	(4)	(5)	(10)	(8)
	EBT margin, %	0.00	0.00	(1,358.01)	(734.38)	(310.78)	(434.26)	(215.59)	(263.05)	(489.96)	(404.07)
	Net income	0	(3)	(3)	(3)	(3)	(6)	(4)	(5)	(10)	(8)
	Depreciation	—	3	0	0	0	3	1	0	4	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.04	0.06	0.14	0.18	0.25	0.26	0.20	0.18
	Earnings	(0.01)	(0.12)	(0.53)	(0.43)	(0.44)	(0.81)	(0.53)	(0.69)	(0.99)	(2.58)
	Cash flow	(0.01)	0.00	(0.18)	(0.14)	(0.04)	(0.35)	(0.35)	(0.44)	(0.44)	(0.44)
	Capex	0.00	0.00	0.00	0.00	0.00	(0.01)	(0.01)	(0.01)	(0.01)	0.00
	Free cash flow	(0.01)	0.00	(0.18)	(0.14)	(0.04)	(0.36)	(0.36)	(0.45)	(0.44)	(0.44)
	Book value	0.00	0.01	0.39	0.03	1.06	1.50	1.01	0.81	0.61	0.57
	Shares, m	25	22	6	6	7	8	8	8	11	12
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	0.00	201.26	110.08	20.92	14.85	9.96	41.10	26.81
	P/B	—	—	64.12	425.36	14.61	2.51	3.60	3.22	13.68	8.18
	EV/Sales	—	—	0.00	201.42	110.25	17.60	13.97	9.79	39.14	24.61
	EV/FCF	—	—	(138.53)	(83.08)	(345.35)	(8.66)	(9.48)	(5.70)	(17.75)	(9.75)
Cash, $m
Cash, $m	Operating cash flow	0	0	(1)	(1)	0	(3)	(3)	(4)	(5)	(5)
	Capex	—	—	0	—	—	0	0	0	0	0
	Free cash flow	0	0	(1)	(1)	0	(3)	(3)	(4)	(5)	(5)
Balance, $m
Balance, $m	Working capital	0	0	0	(2)	(2)	5	2	0	4	4
	Total debt	0	0	0	0	0	0	0	0	0	0
	Net debt	0	0	0	0	0	(5)	(2)	0	(4)	(5)
	Shareholders’ equity	0	0	2	0	7	12	9	6	6	7
Returns, %
Returns, %	ROA	(796.32)	(2,637.61)	(224.13)	(108.75)	(48.38)	(56.23)	(40.40)	(64.63)	(139.89)	(400.11)
	ROIC	(1,454.81)	(1,094.32)	(105.69)	(528.95)	(22.51)	(54.03)	(41.82)	(50.54)	(295.49)	(242.88)
	ROE	(2,608.62)	(3,695.57)	(263.74)	(210.98)	(80.49)	(67.18)	(43.89)	(73.08)	(162.94)	(458.49)

Negative figures in brackets.

All 10 years →

Fiscal years to Jan 2026 · latest quarter Jul 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CLLS Cellectis S.A.	$79.9M	— (loss-making)	—	−62.05% (below 0%: shrinking)	n/m	−36.95% (below 0%: shrinking)	100.00%	(340.69%)	Compare
PMN Promis Neurosciences	$78.0M	— (loss-making)	—	0.00%	n/m	−169.46% (below 0%: shrinking)	0.00%	0.00%	Compare
PTHS Pelthos Therapeutics Inc.	$77.6M	— (loss-making)	— (loss-making)	—	n/m	−1,614.99% (below 0%: shrinking)	76.86%	(111.02%)	Compare
TELO Telomir Pharmaceuticals, Inc.	$77.3M	— (loss-making)	—	—	n/m	−45.34% (below 0%: shrinking)	—	0.00%	Compare
NTRB Nutriband Inc.	$76.2M	— (loss-making)	4.6×	−29.72% (below 0%: shrinking)	n/m	+55.46% (above 0%: growing)	41.58%	(203.57%)
CRDF Cardiff Oncology, Inc.	$75.5M	— (loss-making)	— (loss-making)	−14.05% (below 0%: shrinking)	n/m	−41.36% (below 0%: shrinking)	100.00%	(9,245.19%)	Compare
ACRV Acrivon Therapeutics, Inc.	$75.4M	— (loss-making)	—	—	n/m	+12.59% (above 0%: growing)	0.00%	0.00%	Compare
OKYO OKYO Pharma Limited Sponsored ADR	$75.1M	— (loss-making)	—	—	n/m	+37.39% (above 0%: growing)	0.00%	—	Compare
PDSB PDS Biotechnology Corporation	$72.8M	— (loss-making)	—	—	n/m	+69.32% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$76.4M	—	—	−14.05%	—	−39.15%	0.00%	0.00%

All 614 Biotechnology stocks →

Nutriband Inc. (NTRB) key facts

Concern: Nutriband Inc.’s revenue for fiscal 2026 (year ended January 2026) was $2.0 million, down 4.80% from fiscal 2025.
Nutriband Inc. (NTRB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NTRB traded at $6.22, a market capitalization of $76.2 million.
Return on equity was −458.5% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 27.17 (safe zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.